PET scan and EBV test guided treatment for nasal NK/T cell lymphoma
Part of Cancer clinical trials.
This trial uses PET scans and EBV DNA levels to personalize treatment for patients with early-stage nasal NK/T cell lymphoma. It aims to reduce side effects by adjusting therapy based on how well the cancer responds.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been newly diagnosed with a type of nasal lymphoma called extranodal NK/T cell lymphoma
- You are 18 years or older
- Your cancer is in an early stage (Ann Arbor stage I or II)
- You have not received any prior treatment for lymphoma
- You are generally in good health with adequate organ function (heart, liver, kidneys, blood counts)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two different combinations of chemotherapy drugs to see which works better for people with early-stage nasal-type or advanced-stage natural killer/T-cell lymphoma. The goal is to find a more effective treatment with manageable side effects.
This trial tests a treatment plan that uses a combination of a chemotherapy drug (pegaspargase) and radiation therapy, adjusting the treatment based on how well the cancer responds. It aims to improve outcomes for people with early-stage NK/T-cell lymphoma while reducing side effects.
This trial tests a combination of an immunotherapy drug (PD-1 antibody, which helps your immune system fight cancer) and radiation therapy for people with early-stage nasal-type NK/T-cell lymphoma. It aims to see if this approach is safe and effective as a first treatment.
This trial compares an immunotherapy approach to standard chemotherapy as a first step before stem cell transplant for patients with advanced NK/T-cell lymphoma. It aims to see which treatment helps patients better before their own stem cells are transplanted.
This study tests whether patients with a specific type of blood cancer (NK/T-cell lymphoma) in the nose or sinuses who have responded well to chemotherapy can be safely treated with reduced radiation doses instead of standard high-dose radiation. The goal is to reduce side effects while maintaining effective treatment.
This trial tests a treatment approach for people with locally advanced nasopharyngeal cancer using their blood EBV DNA level (a cancer-related virus marker). It may help doctors choose and adjust therapy based on how much of this marker is in your blood after standard treatment.
Hear when a new NK-T-Cell Lymphoma, Extranodal trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.